A Phase 3 Study of 131I-Metaiodobenzylguanidine (131I-MIBG) or Crizotinib Added to Intensive Therapy for Children with Newly Diagnosed High-Risk Neuroblastoma (NBL) (IND# 134379)

Sponsor:

COG

Sponsor Study ID:

ANBL1531

CTO #:

102945

NCT Number:

NCT03126916

Phase:

III

Protocol Type:

Treatment

Age Group:

Children

Disease Sites:

Brain and Nervous System

Study Objectives:

This partially randomized phase III trial studies iobenguane I-131 or crizotinib and standard therapy in treating younger patients with newly-diagnosed high-risk neuroblastoma or ganglioneuroblastoma. Radioactive drugs, such as iobenguane I-131, may carry radiation directly to tumor cells and not harm normal cells. Crizotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving iobenguane I-131 or crizotinib and standard therapy may work better in treating younger patients with neuroblastoma or ganglioneuroblastoma.

eConsent:

Not available

Study Documents:

Open Study Documents
(MUSC NetID required for document access)